Synucure Therapeutics’ Scientific Advisory Board brings together international experts in neurology, neurogenetics, neuropsychiatry, and movement disorders.
Established to support the company in developing innovative treatments for Parkinson’s disease, the board provides independent expertise on Synucure’s scientific and clinical directions.
Dr. Camila Aquino
MD, MSc, PhD
- Neurologist at the University of Calgary and Assistant Professor, she specializes in Parkinson’s disease and movement disorders.
- Medical Director of the Deep Brain Stimulation (DBS) Program at the University of Calgary, she is also involved in programs offering advanced therapeutic options for patients with movement disorders.
- She serves on multiple committees of the International Parkinson and Movement Disorder Society, including acting as vice chair of the Clinical Research Methods Special Interest Group.
- Experienced clinical trialist with advanced training in Health Research Methods from McMaster University, specializing in evidence-based medicine, clinical trial design, and outcome evaluation. Her work is supported by competitive research grants and scholarships
and contributes to the development of innovative therapies for movement disorders.
Pr. Roger A. Barker
MD, PhD, FMedSci
- Professor in the Department of Clinical Neurosciences at the University of Cambridge and Honorary Consultant Neurologist at Addenbrooke’s Hospital in Cambridge.
- Lead academic scientist at the Alborada Drug Discovery Institute and the John van Geest Centre for Brain Repair.
- Clinical lead for the regional Huntington’s Disease Clinic.
- Chair of Neurodegeneration at LifeArc and Co-Editor in Chief of the Journal of Neurology.
Pr. Dominique Bonneau
MD, PhD
- Medical geneticist, Professor of Medical Genetics, Head of the Clinical Genetics Unit at Angers University Hospital and affiliated researcher at INSERM.
- Member of the French National Reference Center for Neurogenetic Diseases, with a clinical research focus on neurogenetic disorders, including Huntington’s disease.
- Author and co-author of over 350 publications, with major contributions to the identification of genes involved in rare neurological and developmental disorders.
- Principal Investigator of a clinical trial evaluating cysteamine in Huntington’s disease.
Dr. Ray Dorsey
MD, MBA
- Director of the Center for the Brain & the Environment at the Atria Health and Research Institute.
- Co-author of Ending Parkinson’s Disease and the forthcoming The Parkinson’s Plan.
- Previously led the movement disorders division at Johns Hopkins, directed the Center for Health + Technology at the University of Rochester, chaired the international Huntington Study Group, and consulted for McKinsey & Company.
- Named a “Champion for Change” for Parkinson’s disease by the White House in 2015.
Dr. Christopher A. Ross
MD, PhD
- Professor of Psychiatry, Neurology, Neuroscience, and Pharmacology at Johns Hopkins University School of Medicine. Director of the Division of Neurobiology and the Huntington’s Disease Center at Johns Hopkins.
- Led pioneering work on the Huntingtin protein and the development of cellular and animal models of Huntington’s disease. Also contributed to early imaging studies showing brain atrophy years before clinical symptoms appear.
- Over 20 years of experience consulting for HD research programs across all phases of development, and advising therapeutic program strategy through Scientific Advisory Boards.
- Chair of the Scientific Advisory Council for the Huntington Study Group. Author of over 400 scientific publications, including more than 200 focused on Huntington’s disease.